McDonald MI. N Engl J Med. Agustin ET, Gill V, Domenico P. CSF gram stain in meningitis. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. [Medline]. 2020 Nov 6;15(11):e0241776. 1986 Nov. 13(4):637-45. [Medline]. 1994. E. coli strains to imipene m and meropenem (as i s envisaged in o ur s tudy: Tab le 3) is also in line with a recent study conducted in Lagos, Nigeria which showed Chem Sci. Raveh D(1), Yinnon AM, Broide E, Rudensky B. Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London 75(1B):98-101. 1980 Nov. 27(2):1-56. Postgrad Med J. [Medline]. Infect Dis Prac. eCollection 2020. Usual Pediatric Dose for Meningitis. Among E. coli isolates bla KPC was the only carbapenemase gene detected, and all isolates were susceptible to meropenem-vaborbactam at ≤ 8 µg/ml. 2020 Apr 2;11(17):4403-4409. doi: 10.1039/d0sc01704c. These findings do not support use of piperacillin-tazobactam in this setting. 5. [Medline]. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid. Clinical Case, 2002 Combination therapy with antibiotics that cover E coli plus an antianaerobe can also be used (eg, levofloxacin plus clindamycin or metronidazole). 1994 Nov-Dec. 11(6):277-96. This study investigated the resistome, virulence, plasmids content and clonality of 27 carbapenem resistant E. coli isolated from 27 hospitalized patients at the American University of Beirut Medical Center (AUBMC) in Lebanon between 2012 and 2016. J Crit Ill. 1997. cloacae, E. coli, H. influenzae, K. pneumoniae, P. aeruginosa Anaerobic gram-positive microorganisms: Peptostreptococcus spp. Lerner AM. J Diarrhoeal Dis Res. 18(0):179-211. Meropenem has high affinity for PBP-2, PBP-3, and PBP-4 of E. coli and P. aeruginosa and PBP-1, PBP-2, and PBP-4 of S. Main outcomes and measures: Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Kahlmeter G. JAMA. Meropenem-vaborbactam (MEV) is a novel carbapenem–beta-lactamase inhibitor combination antibiotic approved by the U.S. Food and Drug Administration (FDA) for treatment of complicated urinary tract infections, including pyelonephritis, in adults. It is used to treat community-acquired pneumonia for 7-14 days, acute pyelonephritis and complicated UTI for 10 days, and traveler's diarrhea for 5 days. JAMA. Ortega AM, Cunha BA. 23(3):218-25. No fetal toxicity or malformations were observed in pregnant rats and Cynomolgus monkeys administered intravenous meropenem during organogenesis at doses up to 2.4 and 2.3 times the maximum recommended human dose (MRHD) based on body surface area comparison, respectively; in rats administered intravenous meropenem in late pregnancy and during lactation period, there were no … Relationship between hospital antibiotic use and quinolone resistance in Escherichia coli. 1998. 1985 Nov-Dec. 7 Suppl 4:S778-82. Dr Falcone reported receiving personal fees from MSD, Angelini, and Astellas and grants from Gilead. Dr Rogers reported receiving grants and personal fees from MSD Australia for attending advisory boards and research and personal fees from Mayne Pharma for consulting. Roberts JA. 365(19):1771-80. Lancet. 20:86-8. Palmer DL. A single E coli strain from Turkey (from a surviving patient randomized to meropenem) demonstrated nonsusceptibility to meropenem (MIC, 4 mg/L) via bla OXA-162 (a variant of OXA-48 carbapenemase). [Medline]. Antimicrobials known to be useful in cases of traveler's diarrhea include doxycycline, trimethoprim/sulfamethoxazole (TMP/SMZ), fluoroquinolones, rifaximin, and rifamycin. Cunha BA. 1997 Oct. 314(4):245-9. For broader spectrum coverage, her empirical antibiotic treatment is changed to intravenous meropenem. 1991 Jan. 4(1):80-128. Investigators … (E. coli, Klebsiella, Salmonella) Reduced risk of renal toxicity Dosing Recommendations: For treatment of documented infections sensitive to meropenem, with an MIC ≤ 0.12 g/mL o … The concentration of meropenem in breast milk was evaluated in a study of a 41-year-old woman treated for a postpartum urinary tract infection caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli with meropenem 1 g IV q 8 h. Levels were taken from five samples, and ranged from 0.246 mcg/mL to 0.644 mcg/mL. 1990 Mar. 2(S2):35-40. E coli meningitis requires antibiotics, such as third-generation cephalosporins (eg, ceftriaxone). 2) Limited activity against enterococci. 56(3):853-6, 859-61. E. coli CO strain was recovered from a 50-year-old immunocompromised woman who was hospitalized for a combined liver and heart transplant. Seven E. coli isolates had imipenem MICs ranging from 3 to 16 µg/mL (E-test, AB Biodisk). Shapiro JT, Leboucher G, Myard-Dury AF, Girardo P, Luzzati A, Mary M, Sauzon JF, Lafay B, Dauwalder O, Laurent F, Lina G, Chidiac C, Couray-Targe S, Vandenesch F, Flandrois JP, Rasigade JP. Improved activity against Pseudomonas aeruginosa and Enterobacteriaceae spp. Limited data suggest piperacillin-tazobactam could be equally effective. Chi Hiong U Go, MD Assistant Professor, Department of Internal Medicine, Texas Tech University Health Science Center at Odessa Treat E coli perinephric abscess or prostatitis with at least 6 weeks of antibiotics. Infect Immun. Westphal JF, Brogard JM. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. E. coli, Klebsiella pneumoniae, Klebsiella oxytoca ... Main differences compared to meropenem: 1) Lacks coverage of pseudomonas and acinetobacter. Rifaximin is a nonabsorbed (< 0.4%), broad-spectrum antibiotic specific for enteric pathogens of the GI tract (ie, gram-positive, gram-negative, aerobic, anaerobic). It is used to treat mild-to-moderate UTI for 7-14 days, acute uncomplicated cystitis for 3 days, severe-to-complicated UTI for 7-14 days, infectious diarrhea for 5-7 days, and chronic bacterial prostatitis for 4-6 weeks. [Medline]. Weinberger M, Cytron S, Servadio C, et al. Effects were consistent in an analysis of the per-protocol population. Arch Intern Med. Urinary tract infection: an overview. It is used to treat intra-abdominal infections for 14-21 days. It is indicated for E coli (enterotoxigenic and enteroaggregative strains) associated with travelers' diarrhea. For the very resistant P. aeruginosa, doripenem and meropenem are highly potent because NCI CPTC Antibody Characterization Program. 204(8):1168-75. Ceftriaxone is a third-generation cephalosporin that arrests bacterial growth by binding to one or more penicillin-binding proteins. Glandt M, Adachi JA, Mathewson JJ, Jiang ZD, DiCesare D, Ashley D. Enteroaggregative Escherichia coli as a cause of traveler's diarrhea: clinical response to ciprofloxacin. Carbapenem-Sparing Therapy for Extended-Spectrum β-Lactamase-Producing E coli and Klebsiella pneumoniae Bloodstream Infection: The Search Continues. [Medline]. However, meropenem and doripenem are less active against E. … Larry I Lutwick, MD, FACP Editor-in-Chief, ID Cases; Moderator, Program for Monitoring Emerging Diseases; Adjunct Professor of Medicine, State University of New York Downstate College of Medicine In regard susceptibility of ESBL producing organisms to other antibiotic, 3% E.coli and 18.51% K. pneumoniae are susceptible to quinolone such as levofloxacin, ESBL producing E. coli and K. Whipp SC, Rasmussen MA, Cray WC Jr. 2019 Jun 18;321(23):2370. doi: 10.1001/jama.2019.6706. Amoxicillin interferes with the synthesis of cell wall mucopeptides during active multiplication, resulting in bactericidal activity against susceptible bacteria. Tan JS, File TM. Int J Infect Dis. Short-course therapy of acute cystitis: a brief review of therapeutic strategies. Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP 3rd, Karlowsky JA. Acute focal bacterial pyelonephritis. Combination Therapy with Aminoglycoside in Bacteremiasdue to ESBL-Producing Enterobacteriaceae in ICU. Escherichia coli O157:H7. Drugs. It is given by injection into a vein.. Common side effects include nausea, diarrhea, constipation, headache, rash, and pain at the site of injection. 928598-overview [Medline]. Meropenem and imipenem demonstrate good activity against Enterobacteriaceae, including strains producing ESBLs or AmpC (100% for E coli, 99% for other Enterobacteriaceae), meropenem usually being 2 to 4 fold more potent than imipenem [21–23]. Doxycycline inhibits protein synthesis and thus, bacterial growth, by binding to the 30S and possibly 50S ribosomal subunits of susceptible bacteria. Most Enterococcus faecalis and many Pseudomonas aeruginosa strains, including those resistant to broad-spectrum penicillins and cephalosporins, are susceptible to imipenem, meropenem, and doripenem but are resistant to ertapenem. Piperacillin and tazobactam is an antipseudomonal penicillin plus beta-lactamase inhibitor. 2018 Sep 11;320(10):984-994. doi: 10.1001/jama.2018.12163. 1999 Aug. 29(2):335-8. E coli cholecystitis/cholangitis requires antibiotics such as third-generation cephalosporins that cover E coli and Klebsiella organisms. 1999 Jan. 57(1):81-91. MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN), See this image and copyright information in PMC. •Conclusion: A regimen of 500mg IV q6h is able to achieve a similar probability of target attainment with National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error, Collaborators, Bonoan JT, Mehra S, Cunha BA. It is indicated for traveler’s diarrhea caused by noninvasive strains of E coli not complicated by fever or blood in the stool. 2020 Oct 27;9:e54795. However, reports of community-associated infections caused by ESBL-producing E coli have begun to emerge and this occurrence of community-associated infections due to extended-spectrum β-lactamase (ESBL)–producing Escherichia coli has been recognized among patients without discernible healthcare-associated risk factors in the United States. 12:616-25. Strongyloides stercoralis hyperinfection and central nervous system involvement in a patient with relapsing polychondritis.  Remarkably, high levels of Shiga toxin were detected even when growth of O157:H7 was completely suppressed by CIP. JAMA. For E coli intra-abdominal abscess, antibiotics also must include anaer… Gram positive and gram negative coverage Streptococcus species (incl some Enterococci), Listeria, H. flu, E. coli Proteus mirabilis, Salmonella, Shigella DO NOT USE IF PENICILLINASE PRODUCING Combinations with beta-lactamase inhibitors: Non anti-pseudomonal Amoxicillin plus clavulanate (po - Augmentin) Extends H. flu and Staph coverage 1996. Trial registration: Double Anaerobic Coverage: What is the role in clinical practice? 1991 Dec 30. 2011 Nov 10. Johnson JR. Virulence factors in Escherichia coli urinary tract infection. If you log out, you will be required to enter your username and password the next time you visit. It is active against aerobic gram-negative bacilli. The fluoroquinolones for urinary tract infections: a review. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. 35(3 Suppl):339-42. For patients with Escherichia coli or Klebsiella pneumoniae bloodstream infections and ceftriaxone resistance, treatment with piperacillin-tazobactam compared with meropenem did not result in a non-inferior 30-day mortality, according to data published in the Journal of the American Medical Association (ClinicalTrials.gov identifier: NCT02176122). [Medline]. 2011 Nov 10. Am Fam Physician. Other β-Lactams. 10(2):239-49. 4. EPIDEMIOLOGY OF ESBL E. COLI AND K. PNEUMONIAE UROPATHOGENS. All material on this website is protected by copyright, Copyright © 1994-2020 by WebMD LLC. Since the late 1990s, multidrug-resistant Enterobacteriaceae (mostly E coli) that produce extended-spectrum beta-lactamases (ESBLs), such as the CTX-M enzymes, have emerged within the community setting as an important cause of UTIs. 4. Tabacof J, Feher O, Katz A, et al. DuPont HL. Antimotility agents are contraindicated in children and in persons with enteroinvasive E coli (EIEC) infection. The imipenem and cilastatin combination is for treatment of multiple-organism infections in which other agents do not have wide-spectrum coverage or are contraindicated due to potential for toxicity. 2015 Jan 27;16:24. doi: 10.1186/s13063-014-0541-9. Uncomplicated E coli cystitis can be treated with a single dose of antibiotic or 3-day course of a fluoroquinolone, TMP/SMZ, or nitrofurantoin. [Medline]. Dis Mon. 1993 Jan. 1(1):5-18. Design, setting, and participants: Ampicillin and sulbactam is a drug combination of a beta-lactamase inhibitor with ampicillin. The gram-negative bacillary pneumonias. Uses: As a single agent therapy for the treatment of complicated intraabdominal infections (including appendicitis and peritonitis) due to viridans group streptococci, E coli, K pneumoniae, P aeruginosa, B fragilis, B thetaiotaomicron, Peptostreptococcus species. 2011 Feb. 17(2):180-5. , Recent data from the Canadian national surveillance study, CANWARD, revealed that 868 urine isolates of E coli collected from 2010-2013 were sensitive to fosfomycin using the Clinical and Laboratory Standards Institute (CLSI) agar dilution method, with minimum inhibitory concentrations (MICs) interpreted using CLSI M100-S23 (2013) criteria. 1997 Sep. 11(3):465-83. 1998. Empiric coverage should also include anti–E faecalis coverage. He has also received honoraria from Novartis and AstraZeneca. Patients were randomly assigned 1:1 to intravenous piperacillin-tazobactam, 4.5 g, every 6 hours (n = 188 participants) or meropenem, 1 g, every 8 hours (n = 191 participants) for a minimum of 4 days, up to a maximum of 14 days, with the total duration determined by the treating clinician. Cunha BA. . Dr Harris also reported receiving support to speak at an educational event sponsored by Pfizer. Cunha BA. Get the latest public health information from CDC: https://www.coronavirus.gov. [Medline]. … [Medline]. 18:78-9. [Medline]. Cunha BA. J Am Vet Med Assoc. high-level resistance to mecillinam and low-level resistance to carbapenems, with the exception of meropenem to which these strains were susceptible; in common with TL2740, the combination of imipenem and aztreonam was synergic against these isolates. Donnenberg MS, Kaper JB. She had a history of cardiac failure, hepatitis C virus–related liver cirrhosis, and chronic renal insufficiency. Klein NC, Cunha BA. Matthew E. Levison, Larry M. Bush, in Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (Eighth Edition), 2015. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Citation: Harris PNA et al. 2006 Jan. 254(1):12-8. The next day, urine and blood cultures grow an Escherichia coli producing an extended spectrum β lactamase (ESBL), conferring resistance to cefotaxime and gentamicin but not to meropenem. Conclusions and relevance: 24(2):177-8. 352(9135):1207-12. ... Anaerobic coverage (e.g. It is used to treat pneumonia and complicated UTI for 14 days, bacteremia for 7 days, and intra-abdominal abscess for 14-21 days. is indicated for the treatment of complicated skin and skin structure infections (cSSSI) due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 2018 Sep 11;320(10):979-981. doi: 10.1001/jama.2018.12565. Community-associated extended-spectrum ß-lactamase-producing Escherichia coli infection in the United States. 1994 Apr 15. Drugs. 72(848):361-3. Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE; Antibacterial Resistance Leadership Group. To determine whether definitive therapy with piperacillin-tazobactam is noninferior to meropenem (a carbapenem) in patients with bloodstream infection caused by ceftriaxone-nonsusceptible E coli or K pneumoniae. Pathogenesis of enteric diseases caused by Escherichia coli. lactamase enzymes, meropenem-vaborbactam has limited or no activity, so in the Asia-Paciﬁc region where MLBs are prevalent it was least effective, but and was most effective against US strains where KPC is prevalent. 1996 Jun. Support Care Cancer. Schimpff SC. Infectious Diseases Society of America Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. /viewarticle/938988 Med Clin North Am. We aimed to compare 30-day mortality of patients treated empirically with piperacillin-tazobactam … Escherichia coli on Gram stain. [Medline]. Am Fam Physician. Frank C, Werber D, Cramer JP, Askar M, Faber M, an der Heiden M, et al. [Medline]. [Medline]. 2012 Nov 22. Meropenem is a bactericidal broad-spectrum carbapenem antibiotic that inhibits cell wall synthesis. Ogunbosi BO, Moodley C, Naicker P, Nuttall J, Bamford C, Eley B. PLoS One. [Medline]. 3:57-8. E. coli resistance to Ampicillin-sulbactam is emerging in some areas; check local susceptibility data. Bohnen JM. Extended-spectrum β-lactamases mediate resistance to third-generation cephalosporins (eg, ceftriaxone) in Escherichia coli and Klebsiella pneumoniae. Also, multidrug-resistant strains that produce extended-spectrum beta-lactamases (ESBLs) have emerged as an important cause of community-acquired UTI and sepsis. Enteropathogenic Escherichia coli. Intern Med. Presence of urinary symptoms in bacteremic urinary tract infection: a retrospective cohort study of Escherichia coli bacteremia. Acute and chronic bacterial prostatitis. Escherichia coli sternal osteomyelitis after open heart surgery. Escherichia coli. Levofloxacin is used for infections due to multidrug-resistant gram-negative organisms. Hong S, Zheng DW, Zhang QL, Deng WW, Song WF, Cheng SX, Sun ZJ, Zhang XZ. However, given the broad use of antibiotics in hospitals, a study was performed to determine the relationship between hospital use of 16 classes of antibacterial agents and the incidence of quinolone-resistant E coli isolates. Cunha BA. , Empiric antimicrobial therapy must be comprehensive and cover all likely pathogens in the context of the clinical setting. It is unknown whether ertapenem is associated with similar clinical response and microbiologic cure rates as those achieved … Antib Clinician. Boam WD, Miser WF. Nordmann P. Trends in beta-lactam resistance among Enterobacteriaceae. Infections caused by extended-spectrum β-lactamase (ESBL)–producing gram-negative bacteria are occurring more frequently in hospitalized patients. 1988. Dr Harris reported receiving grants from the Australian Society for Antimicrobials; the International Society for Chemotherapy; the National University Hospital Singapore; the Study, Education, and Research Committee of Pathology; and the Royal College of Pathologists of Australasia Foundation. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid. Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug ReferenceDisclosure: Received salary from Medscape for employment. Prostatic abscess in the antibiotic era. Antibiotics (Basel). [Medline]. 1997. Acute pyelonephritis. Neu HC. Childs SJ. Clin Infect Dis. 1997. Carbapenems (Imipenem, Meropenem, Ertapenem, Doripenem) – all have excellent anaerobic activity. Antibiotics are not useful in enterohemorrhagic E coli (EHEC) infection and may predispose to development of HUS. Noninferiority, parallel group, randomized clinical trial included hospitalized patients enrolled from 26 sites in 9 countries from February 2014 to July 2017. In Vitro Activity of Fosfomycin against Escherichia coli Isolated from Patients with Urinary Tract Infections in Canada; CANWARD Surveillance Study. It is effective against most gram-positive and gram-negative bacteria. [Medline]. It is used to treat intra-abdominal infections for 14-21 days. Mayo Clin Proc. 6(6):344-9. Bacteremic Escherichia coli pneumonia. It is given by injection into a vein.. Common side effects include nausea, diarrhea, constipation, headache, rash, and pain at the site of injection. Acute pyelonephritis and its mimics: Xanthogranulomaotus pyelonephritis and malacoplakia. doi: 10.1002/14651858.CD005197.pub3. Current concepts in the treatment of urinary tract infections and prostatitis. 1998 Aug. 27 Suppl 1:S100-6. E coli pneumonia requires respiratory support, adequate oxygenation, and antibiotics, such as third-generation cephalosporins or fluoroquinolones. American College of Physicians-American Society of Internal Medicine, Alliance for the Prudent Use of Antibiotics, American Association for Physician Leadership, American Association for the Advancement of Science, American Association of University Professors, American Clinical and Climatological Association, Association for Professionals in Infection Control and Epidemiology, Infectious Disease Society for Obstetrics and Gynecology, Southern Society for Clinical Investigation, Southwestern Association of Clinical Microbiology, American Association for the Study of Liver Diseases, American Federation for Clinical Research, International Society for Infectious Diseases. [Medline]. Anaerobic gram-negative microorganisms: Bacteroides spp., Fusobacterium spp. Piperacillin-tazobactam may be an effective "carbapenem-sparing" option to treat extended-spectrum β-lactamase producers. Harris PNA, Tambyah PA, Lye DC, et al. Oral nonabsorbable antibiotic that can be used to treat bacterial infections of the colon. Dr Kanj reported receiving honoraria for speaking and serving on advisory boards for Pfizer, Merck, Bayer, Gilead, Hikma, and Aventis. Paul M, Yahav D, Bivas A, Fraser A, Leibovici L. Cochrane Database Syst Rev. The next day, urine and blood cultures grow an Escherichia coli producing an extended spectrum β lactamase (ESBL), conferring resistance to cefotaxime and gentamicin but not to meropenem. 1984 Dec. 3(6):506-9. Moon HW. NIH [Medline]. [Medline]. [Medline]. 2011 Jul. Kappeli U, Hachler H, Giezendanner N, Beutin L, Stephan R. Human Infections with Non-O157 Shiga Toxin-producing Escherichia coli, Switzerland, 2000-2009. 1991 Aug. 84(8):1055-7. What Is the Risk of Catching the Coronavirus on a Plane? E. coliCO clinical isolate; lane 2, E. coliJF 568 strain expressing OmpC; lane 3, E. coli JF 701 strain lacking OmpC (9). Bai AD, Bonares MJ, Thrall S, Bell CM, Morris AM. A total of 23 of 187 patients (12.3%) randomized to piperacillin-tazobactam met the primary outcome of mortality at 30 days compared with 7 of 191 (3.7%) randomized to meropenem (risk difference, 8.6% [1-sided 97.5% CI, -∞ to 14.5%]; P = .90 for noninferiority). Antimicrob Agents Chemother. Clin Infect Dis. It is used to treat meningitis and bacteremia for 14-21 days and pneumonia, complicated UTI, or pyelonephritis for 14 days. Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae are a common cause of bacteraemia in endemic countries and may be associated with high mortality; carbapenems are considered the drug of choice. Microbiology of pneumonia in the patient at risk. 2008 Mar. Patients with complex cases (eg, those with diabetes, >65 years, or recent history of UTI) are treated with a 7- to 14-day course of antibiotics (eg, levofloxacin, third-generation cephalosporins, or aztreonam). Schindzielorz A, Edberg SC, Bia FJ. E coli meningitis requires antibiotics, such as third-generation cephalosporins (eg, ceftriaxone). Epub 2015 Jan 13. Preventing complications through prompt diagnosis and proper therapy. Dr Paterson reported receiving grants and/or personal fees from Merck, Pfizer, Shionogi, Achaogen, AstraZeneca, Leo Pharmaceuticals, Bayer, GlaxoSmithKline, and Cubist. 2010 Sep. 54(9):3790-8. [Medline]. 21:14-5. Jonas M, Cunha BA. Nitrofurantoin is synthetic nitrofuran and interferes with bacterial carbohydrate metabolism by inhibiting acetylcoenzyme A. Eighty-eight percent of K. pneumoniae isolates were susceptible to meropenem, and 99.8% were susceptible to meropenem-vaborbactam (with a vaborbactam concentration of 8 µg/ml). E. coliCO clinical isolate; lane 2, E. coliJF 568 strain expressing OmpC; lane 3, E. coli JF 701 strain lacking OmpC (9). Adv Intern Med. In multiple studies, meropenem-vaborbactam showed strong in vitro activity against E. coli, Enter-obacter spp., and K. pneumoniae. Contemp Urol. 6 Until 2000, ESBL-producing Enterobacteriaceae caused … Dr Tambyah reported receiving grants from the National University Health System, GlaxoSmithKline, Janssen, Shionogi, Sanofi-Pasteur, Visterra, Baxter, ADAMAS, Merlion Pharmaceuticals, Fabentech, and Inviragen. Clin Infect Dis. Eighty-eight percent of K. pneumoniae isolates were susceptible to meropenem, and 99.8% were susceptible to meropenem-vaborbactam (with a vaborbactam concentration of 8 µg/ml). Charles V Sanders, MD Edgar Hull Professor and Chairman, Department of Internal Medicine, Professor of Microbiology, Immunology and Parasitology, Louisiana State University School of Medicine in New Orleans; Medical Director, Medicine Hospital Center, Charity Hospital and Medical Center of Louisiana at New Orleans; Consulting Staff, Ochsner Medical Center German outbreak of Escherichia coli O104:H4 associated with sprouts. 5. Urosepsis. [Medline]. All isolates were phenotypically ESBL-positive by disk testing (confirmatory test, NCCLS). South Med J. Charles V Sanders, MD is a member of the following medical societies: Alliance for the Prudent Use of Antibiotics, Alpha Omega Alpha, American Association for Physician Leadership, American Association for the Advancement of Science, American Association of University Professors, American Clinical and Climatological Association, American College of Physicians, American Federation for Medical Research, American Geriatrics Society, American Lung Association, American Medical Association, American Society for Microbiology, American Thoracic Society, American Venereal Disease Association, Association for Professionals in Infection Control and Epidemiology, Association of American Medical Colleges, Association of American Physicians, Association of Professors of Medicine, Infectious Disease Society for Obstetrics and Gynecology, Infectious Diseases Society of America, Louisiana State Medical Society, Orleans Parish Medical Society, Royal Society of Medicine, Sigma Xi, Society of General Internal Medicine, Southeastern Clinical Club, Southern Medical Association, Southern Society for Clinical Investigation, Southwestern Association of Clinical Microbiology, The Foundation for AIDS ResearchDisclosure: Receives royalties from Baxter International for: Takeda-receives royalties; UpToDate-receives royalties.